Kayne Anderson Rudnick Investment Management LLC trimmed its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,373 shares of the company’s stock after selling 503 shares during the period. Kayne Anderson Rudnick Investment Management LLC’s holdings in Moderna were worth $2,657,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Hobbs Group Advisors LLC acquired a new position in shares of Moderna in the fourth quarter valued at approximately $664,000. Illinois Municipal Retirement Fund raised its position in Moderna by 22.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock worth $5,519,000 after buying an additional 9,360 shares during the last quarter. Swedbank AB purchased a new position in Moderna during the 1st quarter worth $3,315,000. Wellington Management Group LLP lifted its stake in shares of Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Moderna in the first quarter valued at about $2,693,000. Institutional investors and hedge funds own 75.33% of the company’s stock.
Insider Activity at Moderna
In other Moderna news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now directly owns 1,442,089 shares of the company’s stock, valued at approximately $174,665,819.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,158 shares of company stock worth $11,167,312. 15.70% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Get Our Latest Analysis on MRNA
Moderna Trading Down 3.4 %
Shares of MRNA stock opened at $65.69 on Monday. The firm’s 50-day simple moving average is $90.07 and its 200-day simple moving average is $110.96. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The firm has a market cap of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.67.
Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same quarter last year, the firm posted ($3.62) earnings per share. Moderna’s revenue was down 29.9% on a year-over-year basis. As a group, equities analysts forecast that Moderna, Inc. will post -9.52 EPS for the current year.
Moderna Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More
- Five stocks we like better than Moderna
- Investing in Travel Stocks Benefits
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- The Basics of Support and Resistance
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Investing in Commodities: What Are They? How to Invest in Them
- MarketBeat Week in Review – 9/16 – 9/20
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.